Premium
Lung cancer screening in Australia and New Zealand: the evidence and the challenge
Author(s) -
Manners David,
Dawkins Paul,
Pascoe Diane,
Crengle Sue,
Bartholomew Karen,
Leong Tracy L.
Publication year - 2021
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.15230
Subject(s) - medicine , lung cancer , lung cancer screening , cancer , intensive care medicine , disease , clinical trial , national lung screening trial , lung disease , family medicine , lung , oncology , pathology
Lung cancer remains the commonest cause of cancer death in Australia and New Zealand. Targeted screening of individuals at highest risk of lung cancer aims to detect early stage disease, which may be amenable to potentially curative treatment. While current policy recommendations in Australia and New Zealand have acknowledged the efficacy of lung cancer screening in clinical trials, there has been no implementation of national programmes. With the recent release of findings from large international trials, the evidence and experience in lung cancer screening has broadened. This article discusses the latest evidence and implications for Australia and New Zealand.